Home › Pituitary Dwarfism › NCT05820672
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
RecruitingObservational study
A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With SKYTROFA (Lonapegsomatropin)
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients who are on treatment with SKYTROFA (lonapegsomatropin) * Patients being clinically managed in USA * Patients with an appropriate written informed consent/assent as applicable for the age of the patient Exclusion Criteria: * Patients participating in any interventional clinical study
About the study
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
What is being tested
- No intervention (other)
Sponsor: Ascendis Pharma Endocrinology Division A/S · Participants: 900 · Started: Mar 20, 2023
Contact the study team
- Deborah Bowlby · Phone: +1 844-442-7236
Official record on ClinicalTrials.gov — NCT05820672
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.